In recent years, tripterygium glycosides combined with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARBs) is also reported to be effective in treating diabetic nephropathy in China, however, the effectiveness of these studies is not consistent, and the reports on safety are not comprehensive. Here, ACE is linked to diabetic kidney disease.